In Brief
This article was originally published in The Tan Sheet
Executive Summary
FDA warns topical pain relievers can cause burns; FDA issues another DMAA warning letter; Senators blast FDA’s lack of caffeine concern; Perrigo faces guaifenesin delays; Mead Johnson gets back on track in China.
You may also be interested in...
Perrigo CEO Seeks To Check Negative Stock Response
Perrigo CEO Joseph Papa tries to reassure analysts that the acquisition of Elan in July did not signal a shift in strategy, but rather an opportunity to better fund the firm’s core strategy to grow through category and geographic expansion. Key categories include ophthalmology, adult nutrition and products for diabetics.
Perrigo CEO Seeks To Check Negative Stock Response
Perrigo CEO Joseph Papa tries to reassure analysts that the acquisition of Elan in July did not signal a shift in strategy, but rather an opportunity to better fund the firm’s core strategy to grow through category and geographic expansion. Key categories include ophthalmology, adult nutrition and products for diabetics.
Mead Johnson Upbeat On China Outlook After Series Of Setbacks
The infant nutritionals firm has put a poorly timed price increase behind it and is optimistic about the effects of a Hong Kong limit on formula exports on China sales. Additionally, a recall of Danone baby nutrition products in Asia is expected to benefit Mead Johnson over the next 9 to 12 months.